Max Robotics — Global Service Robot Directory + US Certification

About

Stefan Kommoss is a leading gynecologic oncologist whose research has reshaped surgical and diagnostic approaches for ovarian and cervical cancers. His work centers on borderline ovarian tumors (BOT), homologous recombination deficiency (HRD) as a biomarker, and de-escalation of radical surgery for low-risk cervical cancer. In the landmark AGO ROBOT study, Kommoss demonstrated that incomplete surgical staging is a negative prognostic factor for BOT patients, with his 2015 analysis of 950 cases (42 citations) clarifying the impact of individual staging procedures. He further advanced precision oncology by evaluating HRD in 514 ovarian carcinoma samples (40 citations), establishing next-generation sequencing of BRCA1/BRCA2 and 26,523 SNPs as a critical tool for targeted therapy decisions. Kommoss contributed to the groundbreaking SHAPE trial (26 citations), an international phase III study that challenged the standard of radical hysterectomy for low-risk early-stage cervical cancer, showing that simple hysterectomy is non-inferior with reduced morbidity. His work on CA125 in BOT diagnosis (14 citations) and the multicenter ROBOT outcomes study (6 citations) further solidified his reputation. Through these contributions, Kommoss has improved risk stratification, surgical de-escalation, and biomarker-driven therapy, directly impacting clinical guidelines and patient outcomes.